Laddar populära aktier...
Redeye returns with a positive view on the back of Bredband2’s Q2 2024 report which was in line with...
Suominen’s results continued gradual improvement from Q1, while fell short of Vara Research consensu...
Adj. EBITA -2% vs. ABGSCe, but very strong cash flow Q2 numbers imply no material adj.
Raute’s Q2 figures were mostly impressive even if smaller order flow remains one source of uncertain...
Etteplan's Q2 fell short of our estimates due to continued low customer activity.
Redeye updates its estimates after reviewing Tessin's Q2 report, which was in line with our expectat...
Redeye provides an update following Optomed’s Q2 report.
Paper EBITDA PLN 50m, below ABGSCe PLN 59m Group EBITDA miss driven by weaker on both paper and pulp...
Redeye thinks the financial development in Q2 was weak, with the only positive surprise (product sal...
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 8 augusti år 2024 att Bolagets läkemedel Zeqmelit®...
Etteplan's Q2 results missed our estimates across the board.
Redeye leaves a comment on Coegin Pharma’s announcement of having secured an exclusive agreement wit...
Redeye notes that Q2 sales and EBIT were lower than anticipated.
CapMan's turnover in Q2 amounted to EUR 18.3m, above our estimates and consensus (EUR 16.
CapMan reported Q2 Adj. EBIT of 5.8m, 4% below LSEG Data & Analytics consensus at EUR 6.
